Key Insights• According to the research report, "Spain Inhalation Devices Market Outlook, 2031," published by Actual Market Research, the Spain Inhalation Devices Market is anticipated to grow at more than 7.54% CAGR from 2026 to 2031.• The adoption of inhalation devices in Spain is underpinned by a heavy burden of chronic respiratory conditions, supported by universal coverage under the National Health System (Sistema Nacional de Salud - SNS). Epidemiological research indicates that approximately 3 million people in Spain live with asthma, while Chronic Obstructive Pulmonary Disease (COPD) affects an estimated 3.2 million adults over the age of 40 (reflecting a regional prevalence rate of nearly 11.8%). Because the SNS reimburses core maintenance and rescue inhalation therapies, patients face minimal out-of-pocket costs, creating a continuous, non-discretionary baseline demand for pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and clinical nebulizers.• A major structural and clinical breakthrough in Spain's respiratory ecosystem is the nationwide accreditation of Specialized Asthma Units (Unidades de Asma Especializadas) led by Spanish scientific societies. Spain has accredited over 100 specialized units across regional hospital centers to manage complex, treatment-resistant respiratory patients. This standardized clinical model optimizes inhaler technique verification, enforces personalized bioequivalent device selection, and tracks inhalation efficiency, significantly reducing acute exacerbations and emergency hospital admissions across autonomous communities.• In response to European Union sustainability goals and national health mandates, Spain is executing an industrial transition toward low Global Warming Potential (low-GWP) propellant systems and propellant-free inhalation tools. Traditional pMDIs relying on high-GWP hydrofluoroalkanes (HFA-134a) are systematically being complemented or replaced by dry powder delivery systems and next-generation pMDIs using eco-friendly propellants like HFA-152a.

Device manufacturers supplying Spanish hospital networks and retail pharmacies are re-engineering valve mechanics and formulation stability to meet stringent Spanish Agency for Medicines and Medical Devices (AEMPS) standards without compromising lung deposition.Market Outlook• Regional health services are expanding digital health initiatives and remote monitoring platforms, enabling primary care physicians and community pharmacists to evaluate inhaler technique, track patient adherence, and manage routine refills locally. This shift drives continuous demand for compact, breath-actuated devices, portable mesh nebulizers, and smart connected inhalers integrated into regional electronic medical record systems.• Key professional bodies guiding clinical protocols, educational programs, and device guidelines include the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), the Spanish Society of Allergology and Clinical Immunology (SEAIC), and the Spanish Agency for Medicines and Medical Devices (AEMPS). The commercial market landscape features major pharmaceutical and device leaders, such as Laboratorios Almirall (a prominent Spanish pharmaceutical innovator), Boehringer Ingelheim España, GlaxoSmithKline (GSK) España, AstraZeneca España, Chiesi España, Teva Pharmaceuticals España, FAES Farma, and Aptar Pharma.Market DynamicsDriver: High disease prevalenceThe primary driver of the Spanish inhalation devices market is the elevated burden of chronic respiratory diseases, backed by comprehensive coverage under the Spanish National Health System (Sistema Nacional de Salud - SNS). Over 3 million people live with asthma in Spain, and Chronic Obstructive Pulmonary Disease (COPD) affects nearly 11.8% of adults aged 40 and older. The SNS provides high reimbursement rates for essential maintenance and rescue inhalation therapies, ensuring low out-of-pocket costs for patients.Challenge: Autonomous community healthcare fragmentationA major challenge facing inhalation device manufacturers in Spain is navigating the decentralized structure of the healthcare system across 17 Autonomous Communities (Comunidades Autónomas). Each autonomous region manages its own healthcare budget, formulary approvals, and public tender processes through regional health services (such as SERMAS in Madrid or CatSalut in Catalonia).Trend: Standardization via specialized asthma units and eco-friendly delivery transitionsA key trend shaping the Spanish market is the nationwide drive toward standardized clinical care through accredited Specialized Asthma Units (Unidades de Asma Especializadas) alongside an environmental push for low-carbon delivery systems.

Accredited by scientific bodies such as the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), these specialized units systematically evaluate patient inhalation technique, monitor adherence, and tailor delivery devices to specific patient capabilities.Segment AnalysisSpain Inhalation Devices By Product Type• The Spain metered dose inhalers market is distinguished by the continued importance of pressurized devices for rapid-relief treatment and for patients who benefit from spacer compatibility. A key market-specific consideration is the environmental impact of hydrofluorocarbon propellants, which has prompted Spanish healthcare authorities to promote more sustainable inhaler prescribing. Nevertheless, MDIs remain clinically important for patients who cannot generate adequate inspiratory flow for some alternative devices or who rely on familiar delivery systems.• The Spain dry powder inhalers market is increasingly associated with sustainable respiratory prescribing because DPIs do not require the greenhouse-gas propellants used in conventional pressurized MDIs. Spanish health guidance supports considering these devices for new patients when their clinical characteristics and inhalation capabilities make them appropriate. Product differentiation centres on effective powder dispersion, moisture protection, reliable dose preparation, intuitive operating mechanisms, and clear feedback that helps patients use the device correctly. A particularly important consideration is matching inspiratory requirements to individual respiratory function, since not every patient can generate sufficient inhalation force, especially during severe symptoms.• The Spain soft mist inhalers market offers a propellant-free delivery option that generates a slowly moving aerosol, providing an alternative to both conventional pressurized inhalers and dry powder systems.

SMIs can reduce coordination demands for some patients and may be suitable for selected maintenance treatments, depending on the prescribed medicine and the user's capabilities. Their relevance has increased alongside Spain's focus on sustainable inhaler prescribing, which explicitly recognizes soft mist devices as lower-carbon options when clinically appropriate.• The Spain nebulizers market is characterized by the use of aerosolized liquid medication in selected clinical situations, including specialist respiratory care, home treatment, and cases where handheld inhalers are unsuitable or a prescribed formulation requires nebulization. Available technologies include compressor-driven, ultrasonic, and vibrating-mesh systems, each with distinct maintenance and medication-compatibility requirements. Manufacturers compete through reliable aerosol generation, portability, reduced noise, ease of cleaning, and accessible replacement components. Spain's pharmacy-based collection and waste-management infrastructure is also relevant to the broader inhalation-device lifecycle, although reusable nebulizer equipment requires different handling from disposable inhalers and cartridges.Spain Inhalation Devices By Therapeutic Application• The Spain asthma inhalation devices market is shaped by individualized treatment selection, the importance of inhaler-technique education, and efforts to improve disease control while reducing the environmental footprint of respiratory care. Device choice varies according to age, inspiratory capability, coordination, prescribed medication, and patient preference.

MDIs with spacers remain important for children and patients who have difficulty coordinating actuation with inhalation, while DPIs and SMIs offer alternatives for appropriately selected patients. Spain's sustainable-prescribing guidance creates opportunities for lower-carbon inhalers when starting treatment or making clinically justified changes, but generally discourages switching patients whose asthma is well controlled solely for environmental reasons.• The Spain COPD inhalation devices market is influenced by long-term maintenance requirements, the practical limitations associated with reduced inspiratory capacity, and the need to simplify treatment for patients managing multiple medicines. Device selection must consider inspiratory strength, manual dexterity, familiarity, and the ability to follow device-specific instructions. Combination inhalers can help simplify prescribed regimens, while SMIs, DPIs, and MDIs provide different delivery options according to individual clinical needs. Nebulizers remain relevant for selected patients who cannot effectively use handheld systems or require medicines specifically intended for nebulization.• The others segment of the Spain inhalation devices market includes respiratory applications beyond asthma and COPD, such as cystic fibrosis, bronchiectasis, selected respiratory infections, and other pulmonary conditions requiring specialized inhaled therapies. These applications may involve specific liquid formulations, complex treatment schedules, and device-cleaning requirements that differ from those of routine maintenance inhalers.

Nebulizers are important for delivering compatible medicines such as selected inhaled antibiotics or saline solutions, while specialized handheld systems may be appropriate for particular therapies. Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Inhalation Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Metered Dose Inhalers (MDIs)• Dry Powder Inhalers (DPIs)• Soft Mist Inhalers (SMIs)• NebulizersBy Therapeutic Application• Asthma• COPD• Others.